‘Immunotherapy in Alzheimer’s disease’ – special series call for submissions

- 0 Comments

Alzheimer’s Research & Therapy is accepting research submissions for consideration in a special series on immunotherapy in Alzheimer’s disease.

Accumulation of amyloid-beta protein (Aβ) and hyperphosphorylated tau protein are the pathological hallmarks of Alzheimer’s disease (AD), the most common form of dementia. The current approved therapies for AD consist of symptomatic treatments, which do not slow down the underlying disease process. Therefore, in the past decade, research has been heavily focussed on finding ‘disease modifying drugs’ that will counteract the progression of AD by intervening in a specific part of the neuropathology.

Immunotherapy has been the most extensively studied approach in Aβ-targeted therapy, and both passive and active immunotherapies have been shown to effectively reduce Aβ pathology in preclinical models. Comparatively, tau immunotherapy is not as advanced, but preclinical data support its rapid development towards clinical trials.

The ‘immunotherapy in Alzheimer’s disease’ special series in Alzheimer’s Research & Therapy will provide an overview of the various attempts (past and ongoing) to modulate the course of Alzheimer’s disease by immunotherapy. This area remains a moving target and the series aims to address the open questions as well as capturing the current state of the field.

The publication of research articles will be co-ordinated with a series of commissioned reviews and opinions written by leaders in the field and edited by Prof Philip Scheltens (VU University Medical Center, Amsterdam). Upcoming contributors include Richard Dodel (University of Marburg), Lars Lannfelt (Uppsala University), Todd Golde (University of Florida) and Bengt Winblad (Karolinska).

The deadline for research submissions is 31st December 2013. Please submit online and indicate in your covering letter that you would like the article to be considered for the immunotherapy series.

Benefits of publishing in Alzheimer’s Research & Therapy include:

• International and rapid peer–review (first decision provided within 6 weeks)
• Prestigious Editorial Board
• Immediate publication on acceptance, no color figure charges or space limits and guaranteed unlimited global visibility for your research that open access publishing provides
• Inclusion in PubMed and PubMed Central and indexed in Web of Science database/Science citation index Expanded (SciSearch)

If you would like to enquire about the suitability of a study for consideration, please email editorial@alzres.com.

Alzheimer’s Research & Therapy is an international, peer-reviewed journal with an Impact Factor of 4.39. For further information about the journal, please visit the website, or contact us for enquires about the special series.